MedTrace Logo

Identifying Subgroups With High Cardiovascular Risk in Breast Cancer Survivors

NCT02485626 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 628

Last updated 2016-10-31

No results posted yet for this study

Summary

The purpose of this study is to evaluate the prevalence of (sub)clinical cardiovascular disease, cardiovascular risk factors and metabolic abnormalities among long-term breast cancer survivors treated with or without anthracyclines in order to identify patients at increased risk of developing cardiovascular disease.

Conditions

Interventions

PROCEDURE

2D tissue doppler echocardiography

Sponsors & Collaborators

  • University Medical Center Groningen

    collaborator OTHER

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Flora E. van Leeuwen, Prof. dr. · The Netherlands Cancer Institute

Eligibility

Min Age
40 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2019-04-30
Completion
2019-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02485626 on ClinicalTrials.gov